Geron (NASDAQ:GERN) Announces Quarterly Earnings Results

Geron (NASDAQ:GERN) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04), Zacks reports. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%.

Geron Stock Performance

GERN stock traded down $0.75 during midday trading on Wednesday, hitting $1.63. 72,719,004 shares of the company traded hands, compared to its average volume of 13,690,789. The stock has a market capitalization of $982.31 million, a price-to-earnings ratio of -5.11 and a beta of 0.53. The business has a 50 day simple moving average of $3.05 and a 200-day simple moving average of $3.83. Geron has a twelve month low of $1.46 and a twelve month high of $5.34. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04.

Wall Street Analyst Weigh In

GERN has been the topic of a number of recent analyst reports. Barclays raised Geron to a “strong-buy” rating in a research note on Friday, November 29th. Needham & Company LLC lifted their target price on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. B. Riley dropped their price target on shares of Geron from $5.50 to $3.50 and set a “buy” rating on the stock in a research note on Tuesday, February 18th. Finally, HC Wainwright lowered Geron from a “buy” rating to a “neutral” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Geron currently has an average rating of “Moderate Buy” and an average price target of $6.91.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.